Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
Astrocytoma
/ drug therapy
Chemotherapy, Adjuvant
Child, Preschool
Female
Humans
Kidney Neoplasms
/ drug therapy
Maintenance Chemotherapy
/ methods
Male
Membrane Glycoproteins
/ genetics
Neoplasm Proteins
/ genetics
Neoplasms, Germ Cell and Embryonal
/ drug therapy
Oncogene Proteins, Fusion
/ genetics
Prognosis
Pyrazoles
/ therapeutic use
Pyrimidines
/ therapeutic use
Receptor, trkB
/ genetics
Repressor Proteins
/ genetics
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
received:
27
06
2020
accepted:
28
09
2020
pubmed:
24
10
2020
medline:
6
1
2022
entrez:
23
10
2020
Statut:
ppublish
Résumé
Treatment-related morbidity drives research to identify targetable lesions in children with cancer. Neurotrophic tropomyosin receptor kinase (NTRK) alterations occur in ~1% of pediatric solid tumors. Early phase pediatric trials involving the NTRK inhibitor treatment for progressive NTRK-mutated cancers show promising results. The authors describe the adjuvant maintenance larotrectinib treatment after definitive surgical resection in 2 toddlers with NTRK fusion-positive malignancies (ETV6-NTRK3 fusion-positive undifferentiated embryonal sarcoma of the kidney and NACC2-NTRK2 fusion-positive anaplastic astrocytoma). Both are alive, in remission, developing normally and tolerating larotrectinib 15 months later, thus extending the NTRK inhibitor therapeutic spectrum by describing the adjuvant maintenance larotrectinib treatment in children with NTRK fusion-positive cancers associated with high recurrences.
Identifiants
pubmed: 33093355
pii: 00043426-202110000-00024
doi: 10.1097/MPH.0000000000001983
doi:
Substances chimiques
ETV6-NTRK3 fusion protein, human
0
Membrane Glycoproteins
0
NACC1 protein, human
0
Neoplasm Proteins
0
Oncogene Proteins, Fusion
0
Pyrazoles
0
Pyrimidines
0
Repressor Proteins
0
Receptor, trkB
EC 2.7.10.1
tropomyosin-related kinase-B, human
EC 2.7.10.1
larotrectinib
PF9462I9HX
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e987-e990Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Kheder ES, Hong DS. Emerging targeted therapy for tumors with. Clin Cancer Res. 2018;24:5807–5814.
Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019;32:147–153.
Davis JL, Lockwood CM, Stohr B, et al. Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol. 2019;43:435–445.
Albert CM, Davis JL, Federman N, et al. TRK fusion cancers in children: a clinical review and recommendations for screening. J Clin Oncol. 2019;37:513–524.
Gambella A, Senetta R, Collemi G, et al. Fusions in central nervous system tumors: a rare, but worthy target. Int J Mol Sci. 2020;21:753.
Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46:444–450.
Pavlick D, Schrock AB, Malicki D, et al. Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer. 2017;64. doi: 10.1002/pbc.26433.
doi: 10.1002/pbc.26433
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731–739.
Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:271–282.
Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–540.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731–747.
Laetsch TW, Hawkins DS. Larotrectinib for the treatment of TRK fusion solid tumors. Expert Rev Anticancer Ther. 2019;19:1–10.
Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19:705–714.
Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31:463–473.
Jones DT, Hutter B, Jäger N, et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013;45:927–932.
Buerki RBA, Zamorski A, Cox M, et al. HGG-15. Successful treatment of an NTRK-fusion positive infantile glioblastoma with larotrectinib, a targeted TRK inhibitor. Neuro-Oncology. 2019;21:ii89–ii90.
Ziegler DS, Wong M, Mayoh C, et al. Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br J Cancer. 2018;119:693–696.
Ricciuti B, Genova C, Crinò L, et al. Antitumor activity of larotrectinib in tumors harboring. Onco Targets Ther. 2019;12:3171–3179.